151 related articles for article (PubMed ID: 38304826)
1. Qualification of a flow cytometry-based method for the evaluation of
Raimo M; Zavoianu AG; Meijs W; Scholten P; Spanholtz J
Heliyon; 2024 Jan; 10(2):e24715. PubMed ID: 38304826
[TBL] [Abstract][Full Text] [Related]
2. Good manufacturing practice production of CD34
de Jonge PKJD; van Hauten PMM; Janssen LD; de Goede AL; Berrien-Elliott MM; van der Meer JMR; Mousset CM; Roeven MWH; Foster M; Blijlevens N; Hobo W; Fehniger TA; Jansen JH; Schaap NPM; Dolstra H
Cancer Immunol Immunother; 2023 Oct; 72(10):3323-3335. PubMed ID: 37477653
[TBL] [Abstract][Full Text] [Related]
3. Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells.
Klöß S; Oberschmidt O; Morgan M; Dahlke J; Arseniev L; Huppert V; Granzin M; Gardlowski T; Matthies N; Soltenborn S; Schambach A; Koehl U
Hum Gene Ther; 2017 Oct; 28(10):897-913. PubMed ID: 28810809
[TBL] [Abstract][Full Text] [Related]
4. Good manufacturing practice-compliant cell sorting and large-scale expansion of single KIR-positive alloreactive human natural killer cells for multiple infusions to leukemia patients.
Siegler U; Meyer-Monard S; Jörger S; Stern M; Tichelli A; Gratwohl A; Wodnar-Filipowicz A; Kalberer CP
Cytotherapy; 2010 Oct; 12(6):750-63. PubMed ID: 20491532
[TBL] [Abstract][Full Text] [Related]
5. Natural killer cells in clinical development as non-engineered, engineered, and combination therapies.
Lamers-Kok N; Panella D; Georgoudaki AM; Liu H; Özkazanc D; Kučerová L; Duru AD; Spanholtz J; Raimo M
J Hematol Oncol; 2022 Nov; 15(1):164. PubMed ID: 36348457
[TBL] [Abstract][Full Text] [Related]
6. Adaptive single-KIR
Haroun-Izquierdo A; Vincenti M; Netskar H; van Ooijen H; Zhang B; Bendzick L; Kanaya M; Momayyezi P; Li S; Wiiger MT; Hoel HJ; Krokeide SZ; Kremer V; Tjonnfjord G; Berggren S; Wikström K; Blomberg P; Alici E; Felices M; Önfelt B; Höglund P; Valamehr B; Ljunggren HG; Björklund A; Hammer Q; Kveberg L; Cichocki F; Miller JS; Malmberg KJ; Sohlberg E
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36319065
[TBL] [Abstract][Full Text] [Related]
7. Validating human induced pluripotent stem cell-specific quality control tests for the release of an intermediate drug product in a Good Manufacturing Practice quality system.
Novoa J; Westra I; Steeneveld E; Neves NF; Daleman L; Asensio AB; Davis RP; Carlotti F; Freund C; Rabelink T; Meij P; Wieles B
Cytotherapy; 2024 Apr; ():. PubMed ID: 38703154
[TBL] [Abstract][Full Text] [Related]
8. Development of Automated Separation, Expansion, and Quality Control Protocols for Clinical-Scale Manufacturing of Primary Human NK Cells and Alpharetroviral Chimeric Antigen Receptor Engineering.
Oberschmidt O; Morgan M; Huppert V; Kessler J; Gardlowski T; Matthies N; Aleksandrova K; Arseniev L; Schambach A; Koehl U; Kloess S
Hum Gene Ther Methods; 2019 Jun; 30(3):102-120. PubMed ID: 30997855
[TBL] [Abstract][Full Text] [Related]
9. Ex vivo expansion of highly purified NK cells for immunotherapy after haploidentical stem cell transplantation in children.
Koehl U; Esser R; Zimmermann S; Tonn T; Kotchetkov R; Bartling T; Sörensen J; Grüttner HP; Bader P; Seifried E; Martin H; Lang P; Passweg JR; Klingebiel T; Schwabe D
Klin Padiatr; 2005; 217(6):345-50. PubMed ID: 16307421
[TBL] [Abstract][Full Text] [Related]
10. An improved flow cytometry-based natural killer cytotoxicity assay involving calcein AM staining of effector cells.
Jang YY; Cho D; Kim SK; Shin DJ; Park MH; Lee JJ; Shin MG; Shin JH; Suh SP; Ryang DW
Ann Clin Lab Sci; 2012; 42(1):42-9. PubMed ID: 22371909
[TBL] [Abstract][Full Text] [Related]
11. Genetic Engineering and Enrichment of Human NK Cells for CAR-Enhanced Immunotherapy of Hematological Malignancies.
Soldierer M; Bister A; Haist C; Thivakaran A; Cengiz SC; Sendker S; Bartels N; Thomitzek A; Smorra D; Hejazi M; Uhrberg M; Scheckenbach K; Monzel C; Wiek C; Reinhardt D; Niktoreh N; Hanenberg H
Front Immunol; 2022; 13():847008. PubMed ID: 35464442
[TBL] [Abstract][Full Text] [Related]
12. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
13. Optimized cytotoxicity assay for co-suspended effector and target cells.
Cui L; Yin F; Cheng J; Liu H; Zheng M; Liu D; Wu Z; Qian Q
J Immunol Methods; 2021 Oct; 497():113100. PubMed ID: 34270976
[TBL] [Abstract][Full Text] [Related]
14. Characterization of FcγRIIIA effector cells used in in vitro ADCC bioassay: Comparison of primary NK cells with engineered NK-92 and Jurkat T cells.
Hsieh YT; Aggarwal P; Cirelli D; Gu L; Surowy T; Mozier NM
J Immunol Methods; 2017 Feb; 441():56-66. PubMed ID: 27939300
[TBL] [Abstract][Full Text] [Related]
15. Clinical-grade, large-scale, feeder-free expansion of highly active human natural killer cells for adoptive immunotherapy using an automated bioreactor.
Sutlu T; Stellan B; Gilljam M; Quezada HC; Nahi H; Gahrton G; Alici E
Cytotherapy; 2010 Dec; 12(8):1044-55. PubMed ID: 20795758
[TBL] [Abstract][Full Text] [Related]
16. Anti-TIM3 chimeric antigen receptor-natural killer cells from engineered induced pluripotent stem cells effectively target acute myeloid leukemia cells.
Klaihmon P; Luanpitpong S; Kang X; Issaragrisil S
Cancer Cell Int; 2023 Nov; 23(1):297. PubMed ID: 38012684
[TBL] [Abstract][Full Text] [Related]
17. [Cytotoxicity of allogenetic natural killer cells against CD34+ acute myelogenous leukemia cells].
Niu XQ; Guo KY; Zhou J; Hu LS; Tu SF; She MR
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Feb; 28(2):173-5. PubMed ID: 18250035
[TBL] [Abstract][Full Text] [Related]
18. How can Cytokine-induced killer cells overcome CAR-T cell limits.
Cappuzzello E; Vigolo E; D'Accardio G; Astori G; Rosato A; Sommaggio R
Front Immunol; 2023; 14():1229540. PubMed ID: 37675107
[TBL] [Abstract][Full Text] [Related]
19. Low Energy Electron Irradiation Is a Potent Alternative to Gamma Irradiation for the Inactivation of (CAR-)NK-92 Cells in ATMP Manufacturing.
Walcher L; Kistenmacher AK; Sommer C; Böhlen S; Ziemann C; Dehmel S; Braun A; Tretbar US; Klöß S; Schambach A; Morgan M; Löffler D; Kämpf C; Blumert C; Reiche K; Beckmann J; König U; Standfest B; Thoma M; Makert GR; Ulbert S; Kossatz-Böhlert U; Köhl U; Dünkel A; Fricke S
Front Immunol; 2021; 12():684052. PubMed ID: 34149724
[TBL] [Abstract][Full Text] [Related]
20. Engineering Natural Killer Cells for Cancer Immunotherapy.
Rezvani K; Rouce R; Liu E; Shpall E
Mol Ther; 2017 Aug; 25(8):1769-1781. PubMed ID: 28668320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]